FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4281867609> ?p ?o ?g. }

• W4281867609 abstract "Background We have previously shown that 15 urinary biomarkers (of 129 tested by Luminex), discriminate between active Lupus Nephritis (ALN) and non-LN patients. The aim of this study was to evaluate the ability of these 15 previously-identified urinary biomarkers to predict treatment responses to conventional therapy, and for the most predictive of these biomarkers to validate their utility to identify ALN patients in an independent prospectively-acquired lupus cohort. Methods Our study had a 3-stage approach. In stage 1, we used Luminex to examine whether our previously identified urinary biomarkers at the time of the renal flare ( ± 3 months) or 12 ± 3 months after treatment of biopsy-proven ALN could predict treatment responses. In stage 2, a larger prospectively-acquired cross-sectional cohort was used to further validate the utility of the most predictive urinary biomarkers (identified in stage 1) to detect ALN patients. In this 2 nd stage, cut-offs with the best operating characteristics to detect ALN patients were produced for each biomarker and different combinations and/or numbers of elevated biomarkers needed to accurately identify ALN patients were analyzed. In stage 3, we aimed to further corroborate the sensitivity of the cut-offs created in stage 2 to detect ALN patients in a biopsy-proven ALN cohort who had a urine sample collection within 3 months of their biopsy. Results Twenty-one patients were included in stage 1. Twelve (57.1%), 4 (19.1%), and 5 (23.8%) patients had a complete (CR), partial (PR) and no (NR) remission at 24 ± 3 months, respectively. The percentage decrease following 12 ± 3 months of treatment for Adiponectin, MCP-1, sVCAM-1, PF4, IL-15 and vWF was significantly higher in patients with CR in comparison to those with PR/NR. In stage 2, a total of 247 SLE patients were included, of which 24 (9.7%) had ALN, 79 (31.9%) had LN in remission (RLN) and 144 (58.3%) were non-LN (NLN) patients. Based on the combinations of biomarkers with the best operating characteristics we propose “rule out” and “rule in” ALN criteria. In stage 3, 53 biopsy-proven ALN patients were included, 35 with proliferative LN and 18 with non-proliferative ALN, demonstrating that our “rule in ALN” criteria operate better in detecting active proliferative than non-proliferative classes. Conclusions Our results provide further evidence to support the role of Adiponectin, MCP-1, sVCAM-1 and PF4 in the detection of proliferative ALN cases. We further show the clinical utility of measuring multiple rather than a single biomarker and we propose novel “rule in” and “rule out” criteria for the detection of proliferative ALN with excellent operating characteristics." @default.
• W4281867609 created "2022-06-13" @default.
• W4281867609 creator A5003819915 @default.
• W4281867609 creator A5011252269 @default.
• W4281867609 creator A5037716667 @default.
• W4281867609 creator A5049009339 @default.
• W4281867609 creator A5049489990 @default.
• W4281867609 creator A5053625208 @default.
• W4281867609 creator A5057593975 @default.
• W4281867609 creator A5062506424 @default.
• W4281867609 creator A5079988966 @default.
• W4281867609 creator A5090991465 @default.
• W4281867609 date "2022-05-30" @default.
• W4281867609 modified "2023-10-04" @default.
• W4281867609 title "Identification and Validation of a Urinary Biomarker Panel to Accurately Diagnose and Predict Response to Therapy in Lupus Nephritis" @default.
• W4281867609 cites W1566236740 @default.
• W4281867609 cites W1795240072 @default.
• W4281867609 cites W1903248918 @default.
• W4281867609 cites W1939623701 @default.
• W4281867609 cites W1963691526 @default.
• W4281867609 cites W1994363964 @default.
• W4281867609 cites W1998641623 @default.
• W4281867609 cites W2003063024 @default.
• W4281867609 cites W2003941029 @default.
• W4281867609 cites W2004822369 @default.
• W4281867609 cites W2012285989 @default.
• W4281867609 cites W2012552107 @default.
• W4281867609 cites W2016884158 @default.
• W4281867609 cites W2017460912 @default.
• W4281867609 cites W2021988356 @default.
• W4281867609 cites W2029878401 @default.
• W4281867609 cites W2034449234 @default.
• W4281867609 cites W2040188620 @default.
• W4281867609 cites W2043495489 @default.
• W4281867609 cites W2063414048 @default.
• W4281867609 cites W2070527591 @default.
• W4281867609 cites W2081386131 @default.
• W4281867609 cites W2087386412 @default.
• W4281867609 cites W2102857373 @default.
• W4281867609 cites W2108992054 @default.
• W4281867609 cites W2114669539 @default.
• W4281867609 cites W2116420668 @default.
• W4281867609 cites W2117455027 @default.
• W4281867609 cites W2120073512 @default.
• W4281867609 cites W2125995351 @default.
• W4281867609 cites W2127316787 @default.
• W4281867609 cites W2128274902 @default.
• W4281867609 cites W2134338422 @default.
• W4281867609 cites W2138889351 @default.
• W4281867609 cites W2141720478 @default.
• W4281867609 cites W2146444493 @default.
• W4281867609 cites W2151779481 @default.
• W4281867609 cites W2160382588 @default.
• W4281867609 cites W2165568411 @default.
• W4281867609 cites W2178465185 @default.
• W4281867609 cites W2298285162 @default.
• W4281867609 cites W2415025654 @default.
• W4281867609 cites W2415176440 @default.
• W4281867609 cites W2419906038 @default.
• W4281867609 cites W2520880294 @default.
• W4281867609 cites W2528019479 @default.
• W4281867609 cites W2613529089 @default.
• W4281867609 cites W2621345974 @default.
• W4281867609 cites W2626155976 @default.
• W4281867609 cites W2754406772 @default.
• W4281867609 cites W2759047915 @default.
• W4281867609 cites W2766947161 @default.
• W4281867609 cites W2782627377 @default.
• W4281867609 cites W2802773414 @default.
• W4281867609 cites W2946256512 @default.
• W4281867609 cites W3014011850 @default.
• W4281867609 cites W3021154423 @default.
• W4281867609 cites W3022383804 @default.
• W4281867609 cites W3081171410 @default.
• W4281867609 cites W3095635875 @default.
• W4281867609 cites W3095697336 @default.
• W4281867609 cites W3099943271 @default.
• W4281867609 cites W4211032047 @default.
• W4281867609 doi "https://doi.org/10.3389/fimmu.2022.889931" @default.
• W4281867609 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35711439" @default.
• W4281867609 hasPublicationYear "2022" @default.
• W4281867609 type Work @default.
• W4281867609 citedByCount "4" @default.
• W4281867609 countsByYear W42818676092022 @default.
• W4281867609 countsByYear W42818676092023 @default.
• W4281867609 crossrefType "journal-article" @default.
• W4281867609 hasAuthorship W4281867609A5003819915 @default.
• W4281867609 hasAuthorship W4281867609A5011252269 @default.
• W4281867609 hasAuthorship W4281867609A5037716667 @default.
• W4281867609 hasAuthorship W4281867609A5049009339 @default.
• W4281867609 hasAuthorship W4281867609A5049489990 @default.
• W4281867609 hasAuthorship W4281867609A5053625208 @default.
• W4281867609 hasAuthorship W4281867609A5057593975 @default.
• W4281867609 hasAuthorship W4281867609A5062506424 @default.
• W4281867609 hasAuthorship W4281867609A5079988966 @default.
• W4281867609 hasAuthorship W4281867609A5090991465 @default.
• W4281867609 hasBestOaLocation W42818676091 @default.
• W4281867609 hasConcept C126322002 @default.
• W4281867609 hasConcept C126894567 @default.
• W4281867609 hasConcept C143998085 @default.

• next